Compare LEN & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEN | DGX |
|---|---|---|
| Founded | 1954 | 1967 |
| Country | United States | United States |
| Employees | 12532 | N/A |
| Industry | Homebuilding | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.3B | 22.6B |
| IPO Year | N/A | 1996 |
| Metric | LEN | DGX |
|---|---|---|
| Price | $90.93 | $203.09 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 15 | 13 |
| Target Price | $97.23 | ★ $214.38 |
| AVG Volume (30 Days) | ★ 2.4M | 653.1K |
| Earning Date | 06-15-2026 | 04-21-2026 |
| Dividend Yield | ★ 2.25% | 1.82% |
| EPS Growth | N/A | ★ 13.78 |
| EPS | N/A | ★ 2.24 |
| Revenue | N/A | ★ $11,035,000,000.00 |
| Revenue This Year | N/A | $7.53 |
| Revenue Next Year | $4.41 | $3.77 |
| P/E Ratio | ★ $15.20 | $90.89 |
| Revenue Growth | N/A | ★ 11.78 |
| 52 Week Low | $81.18 | $164.65 |
| 52 Week High | $144.24 | $213.50 |
| Indicator | LEN | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 62.81 |
| Support Level | $90.21 | $200.94 |
| Resistance Level | $92.58 | $205.00 |
| Average True Range (ATR) | 2.77 | 4.21 |
| MACD | 0.45 | 1.20 |
| Stochastic Oscillator | 38.67 | 74.31 |
Lennar is the second-largest public homebuilder in the United States, behind D.R. Horton, operating in 26 states. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.